7 Gaps That Kill Cannabis M&A Deals in Diligence

By Daniel Sabet · Cannabis CFO & Financial Advisor, GreenGrowth CPAs · 280E, Tax Strategy & Growth Planning · Los Angeles, CA  |  Published August 2026  |  Cannabis Advisory

Cannabis M&A deals rarely fall apart over price. They fall apart in diligence, when a buyer finds something the seller never knew was there. So the seven gaps below are not exotic. Each is ordinary, each is fixable, and each becomes expensive at exactly the moment you lose the ability to fix it. What they share is timing. Found twelve months out, most cost nothing. Discovered during diligence, they become a price reduction, an escrow holdback, or a walk-away.

Cannabis M&A Deal Killers: At a Glance

The Seven Cannabis M&A Gaps, and What Each Costs You

• 1. Licence transferability: Most states require regulator approval for a change of control, and some restrict transfer entirely.
• 2. Records that disagree: When seed-to-sale, point of sale and the ledger conflict, a buyer discounts the whole business rather than untangling it.
• 3. Undocumented 280E position: An aggressive cost of goods sold allocation with no methodology memo is exposure that transfers to the buyer.
• 4. Related party leases: Where the owner also holds the property, reported earnings are not what a buyer would inherit.
• 5. Informal equity: Promises made verbally, unissued options and an unreconciled cap table stop a deal cold.
• 6. Unaudited financials: The discount for uncertainty frequently exceeds the cost of the audit that would have prevented it.
• 7. Revenue concentration: Wholesale revenue sitting in a handful of retail accounts is fragile, and buyers price fragility.

Why Cannabis M&A Deals Break in Diligence

A cannabis M&A buyer is doing something a conventional buyer is not. Alongside the usual financial review, they are assessing regulatory risk they will inherit, tax positions taken under a statute with almost no favourable case law, and records generated by systems that were never built to agree with each other.

Consequently the tolerance for surprises is low. In an ordinary transaction a discovered issue gets quantified and negotiated. Within cannabis M&A the same issue often triggers a broader question: if this was missed, what else is wrong?

That is why sequencing matters more than substance here. A seller who surfaces a problem first controls how it gets framed. Waiting to be asked loses that advantage entirely.

1. The Licence Cannot Transfer Cleanly

This one kills more cannabis M&A transactions than any other, because it is structural rather than financial. Most states require regulator approval for a change of ownership or control, and that process runs in months rather than weeks. Some restrict transfer outright. Others impose residency, social equity or ownership conditions that disqualify particular buyers entirely.

A licence carrying scarcity value in a capped state is worth nothing to a buyer who cannot receive it. Therefore transferability belongs in the valuation conversation rather than the closing checklist, and a deal structured to avoid a transfer is a different deal at a different price.

2. Three Systems That Do Not Reconcile

Most operators run seed-to-sale for compliance, a point of sale for transactions, and an accounting system for money. Different vendors built each one for a different purpose, and nothing requires them to agree.

When a buyer requests revenue for a period and receives three different figures, the negotiation changes character. Instead of arguing about a multiple, they start discounting for uncertainty across the entire business. Meanwhile you are now defending your credibility rather than your price.

3. An Undocumented Section 280E Position

Cost of goods sold is the only deduction Section 280E permits for adult-use activity, so operators push everything defensible into it. That is reasonable. What is not reasonable is doing it without writing down why.

In an equity purchase the buyer inherits that position. An aggressive allocation with no methodology memo behind it, an amended return claiming a 280E refund, or an unresolved examination all transfer with the entity. Accordingly diligence quantifies the exposure and prices it, usually as a purchase price reduction or an escrow holdback.

Since April 2026 there is a second layer. Dual-licence operators now split costs between medical activity outside 280E and adult-use activity within it, and the IRS has published no default method. A buyer will ask which method you chose and why. Our guide to 280E audit defence sets out what that file should contain.

4. Related Party Leases at Non-Market Rates

Cannabis real estate is frequently held by the same people who own the operating business, often for good reasons involving lending and licensing. The rent charged between them, however, is rarely a market rate.

Set below market, reported earnings overstate what a buyer would actually inherit, since they will pay a real rent. Priced above market to move income into the property entity, earnings understate the business. Either way a buyer normalises it, and the adjustment moves the price.

5. Equity Promised but Never Papered

Cannabis companies grew fast under capital constraints, so early contributors were often paid in promises. A percentage mentioned in a conversation. Options discussed but never granted. A consultant told they would be taken care of at exit.

None of that appears on a cap table, yet all of it surfaces the moment a transaction becomes public. Furthermore a buyer cannot close against an unresolved ownership claim, so this gap stops deals rather than repricing them.

6. Financials Nobody Independent Has Examined

Plenty of profitable operators have never had an audit or even a review, because nothing forced one. A buyer facing unexamined financials has two options: spend heavily on diligence, or discount for uncertainty. Most do both.

That discount is regularly larger than the audit fee that would have removed it. Even a review, which costs considerably less than a full audit, changes the conversation. Our audit and assurance services cover both.

7. Revenue Sitting in Too Few Accounts

A cultivator or processor selling into a handful of retail accounts has concentration risk, and buyers price it heavily. If one account is a quarter of revenue, the buyer is underwriting the possibility that the account leaves with you.

Retail is usually safer, since a repeat customer base transfers with the location. Nevertheless a retailer dependent on one product line or one supplier relationship carries the same problem in a different shape.

The Pattern Underneath All Seven

Read the seven cannabis M&A gaps together and something becomes obvious. Not one is a valuation problem. Every one is a bookkeeping, tax or documentation problem that only becomes visible when somebody outside looks closely.

Notice that most of this work is worth doing whether or not you ever sell. A business with reconciled records, a documented tax position and examined financials is simply easier to run. The transaction just makes the cost of not doing it visible.

How GreenGrowth CPAs Closes These Gaps

We have worked with cannabis operators since 2016 and hold PCAOB registration alongside AICPA membership. That matters in cannabis M&A, because six of the seven gaps are accounting problems rather than deal problems. Brokers cannot close any of them.

A cannabis M&A deal readiness review works through all seven against your business. It tells you which a buyer would find, which are still fixable inside your timeline, and what closing each actually involves. No cost, about an hour.

From there the work is ordinary rather than transactional. Reconciliation, 280E documentation, monthly close discipline, and getting financials to a standard a buyer accepts. For the valuation side of the same question, read our guide to cannabis business valuation, and see the wider practice on our cannabis accounting page.

Cannabis M&A Questions Answered

Where Deals Break

What kills most cannabis M&A deals?+

Licence transferability, more than any other single item. Most states require regulator approval for a change of ownership or control, that process runs in months, and some states restrict transfer entirely or impose conditions that disqualify particular buyers. A licence a buyer cannot receive is worth nothing to them, however valuable it looks on paper.

Why do reconciliation problems matter so much in cannabis M&A?+

Because they change what the negotiation is about. When a buyer asks for revenue and gets three different figures from seed-to-sale, the point of sale and the ledger, they stop arguing about the multiple and start discounting for uncertainty across the whole business. You then find yourself defending your credibility rather than your price.

Does the buyer inherit my 280E tax position?+

In an equity purchase, generally yes. An aggressive cost of goods sold allocation with no methodology memo, an amended return claiming a 280E refund, or an unresolved examination all transfer with the entity. Diligence quantifies the exposure and prices it, usually as a purchase price reduction or an escrow holdback.

Structure and Equity

How do related party leases affect a cannabis deal?+

The rent between an owner-held property and the operating business is rarely a market rate. Set below market, reported earnings overstate what a buyer inherits, because they will pay real rent. Priced above market to move income into the property entity, earnings understate the business. Either way a buyer normalises it and the adjustment moves the price.

What happens if equity was promised but never documented?+

It stops the deal rather than repricing it. A buyer cannot close against an unresolved ownership claim, and verbal promises surface the moment a transaction becomes public. Reconcile the cap table to signed documents early, and resolve every informal promise while the conversation is still friendly rather than adversarial.

Timing and Next Steps

Do I need audited financials to sell a cannabis business?+

Not strictly, although unexamined financials leave a buyer two options: spend heavily on diligence, or discount for uncertainty. Most do both, and that discount regularly exceeds the audit fee that would have removed it. Even a review, which costs considerably less than a full audit, changes the conversation. This is the gap with the longest lead time, since two years of examined financials is the usual expectation.

How far ahead of a sale should I start fixing these?+

Twelve to eighteen months, because lead times differ enormously. A 280E methodology memo takes days. Reconciliation takes weeks to set up. A cap table cleanup takes weeks to months. Audited financials take one to two years. Revenue diversification is an operating change and takes longest of all. Read the lead times first, since they tell you which gaps you can still close.

Working With GreenGrowth CPAs

How does GreenGrowth CPAs help close these gaps?+

A deal readiness review works through all seven against your business and tells you which a buyer would find, which are still fixable in your timeline, and what closing each involves. From there the work is ordinary rather than transactional: reconciliation, 280E documentation, monthly close discipline, and getting financials to a standard a buyer accepts. GreenGrowth CPAs has served cannabis operators since 2016.